PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
30239062-0	2019	Hepcidin-25/erythroferrone ratio predicts improvement of anaemia in haemodialysis patients treated with ferric citrate hydrate.	ferric citrate	104-126	erythroferrone	Homo sapiens	0-26
31278194-6	2019	Ferric citrate coordination complex significantly increased hemoglobin, transferrin saturation, and serum ferritin, and it significantly reduced serum phosphate and intact FGF23 (P<0.001 for all).	ferric citrate	0-14	transferrin	Homo sapiens	72-83
31278194-6	2019	Ferric citrate coordination complex significantly increased hemoglobin, transferrin saturation, and serum ferritin, and it significantly reduced serum phosphate and intact FGF23 (P<0.001 for all).	ferric citrate	0-14	fibroblast growth factor 23	Homo sapiens	172-177
30239062-7	2019	RESULTS: In the FCH group, Hb, transferrin saturation, ferritin, HEP-25 and ERFE levels were all significantly increased, while inorganic phosphorus levels, dosage of erythropoietin-stimulating agent, and erythropoietin resistance index were all significantly decreased after drug administration.	ferric citrate	16-19	transferrin	Homo sapiens	31-42
30239062-7	2019	RESULTS: In the FCH group, Hb, transferrin saturation, ferritin, HEP-25 and ERFE levels were all significantly increased, while inorganic phosphorus levels, dosage of erythropoietin-stimulating agent, and erythropoietin resistance index were all significantly decreased after drug administration.	ferric citrate	16-19	erythroferrone	Homo sapiens	76-80
30239062-7	2019	RESULTS: In the FCH group, Hb, transferrin saturation, ferritin, HEP-25 and ERFE levels were all significantly increased, while inorganic phosphorus levels, dosage of erythropoietin-stimulating agent, and erythropoietin resistance index were all significantly decreased after drug administration.	ferric citrate	16-19	erythropoietin	Homo sapiens	167-181
30239062-7	2019	RESULTS: In the FCH group, Hb, transferrin saturation, ferritin, HEP-25 and ERFE levels were all significantly increased, while inorganic phosphorus levels, dosage of erythropoietin-stimulating agent, and erythropoietin resistance index were all significantly decreased after drug administration.	ferric citrate	16-19	erythropoietin	Homo sapiens	205-219
30239062-11	2019	CONCLUSION: HEP-25/ERFE ratio could be a novel prognostic marker for increases in Hb levels following FCH administration.	ferric citrate	102-105	erythroferrone	Homo sapiens	12-23
30380116-0	2019	Effect of ferric citrate on serum phosphate and fibroblast growth factor 23 among patients with nondialysis-dependent chronic kidney disease: path analyses.	ferric citrate	10-24	fibroblast growth factor 23	Homo sapiens	48-75
30380116-1	2019	BACKGROUND: Among patients with nondialysis-dependent chronic kidney disease (NDD-CKD) and iron-deficiency anemia (IDA), ferric citrate increases hemoglobin and iron parameters and reduces serum phosphate and fibroblast growth factor 23 (FGF23), a key phosphate-regulating hormone.	ferric citrate	121-135	fibroblast growth factor 23	Homo sapiens	209-236
30380116-1	2019	BACKGROUND: Among patients with nondialysis-dependent chronic kidney disease (NDD-CKD) and iron-deficiency anemia (IDA), ferric citrate increases hemoglobin and iron parameters and reduces serum phosphate and fibroblast growth factor 23 (FGF23), a key phosphate-regulating hormone.	ferric citrate	121-135	fibroblast growth factor 23	Homo sapiens	238-243
30380116-3	2019	METHODS: We employed multivariable regression and longitudinal mixed-effects models to identify and confirm, respectively, whether baseline demographic and laboratory variables were associated with ferric citrate-induced changes in serum phosphate or FGF23 concentrations.	ferric citrate	198-212	fibroblast growth factor 23	Homo sapiens	251-256
30380116-7	2019	Ferric citrate reduced intact FGF23 and C-terminal FGF23 partially via changes in TSAT (for C-terminal FGF23) and serum phosphate (for intact FGF23) and partially via unknown/unmeasured mechanisms.	ferric citrate	0-14	fibroblast growth factor 23	Homo sapiens	30-35
30380116-7	2019	Ferric citrate reduced intact FGF23 and C-terminal FGF23 partially via changes in TSAT (for C-terminal FGF23) and serum phosphate (for intact FGF23) and partially via unknown/unmeasured mechanisms.	ferric citrate	0-14	fibroblast growth factor 23	Homo sapiens	51-56
30380116-7	2019	Ferric citrate reduced intact FGF23 and C-terminal FGF23 partially via changes in TSAT (for C-terminal FGF23) and serum phosphate (for intact FGF23) and partially via unknown/unmeasured mechanisms.	ferric citrate	0-14	fibroblast growth factor 23	Homo sapiens	51-56
30380116-7	2019	Ferric citrate reduced intact FGF23 and C-terminal FGF23 partially via changes in TSAT (for C-terminal FGF23) and serum phosphate (for intact FGF23) and partially via unknown/unmeasured mechanisms.	ferric citrate	0-14	fibroblast growth factor 23	Homo sapiens	51-56
30380116-8	2019	CONCLUSIONS: Ferric citrate reduced serum FGF23 concentrations (partially via effects on serum phosphate and iron balance) and did not reduce serum phosphate among patients with baseline serum phosphate concentrations within the population reference range.	ferric citrate	13-27	fibroblast growth factor 23	Homo sapiens	42-47
29956006-7	2018	Compared to the pre-ferric citrate period, ferric citrate treatment was associated with decreased serum phosphate (6.5 to 5.2 mg/dl, p = 0.014), decreased phosphate age-related standard deviation score (SDS) (2.3 to 0.9, p = 0.019), increased transferrin saturation (26 to 34%, p = 0.049), increased ferritin (107 to 230 ng/ml, p = 0.074), and maintenance of hematocrit.	ferric citrate	43-57	transferrin	Homo sapiens	243-254
30236787-8	2019	When physiologically relevant concentrations are used the window of redox opportunity ranges from +0.1 V to +0.9 V. The electrode potential for non-transferrin-bound iron in the form of iron citrate is close to 0 V and the reduction of iron(III) citrate by ascorbate is slow.	ferric citrate	186-198	transferrin	Homo sapiens	148-159
30236787-8	2019	When physiologically relevant concentrations are used the window of redox opportunity ranges from +0.1 V to +0.9 V. The electrode potential for non-transferrin-bound iron in the form of iron citrate is close to 0 V and the reduction of iron(III) citrate by ascorbate is slow.	ferric citrate	236-253	transferrin	Homo sapiens	148-159
30988246-10	2019	In addition, ferric citrate administration reduced the size of cardiomyocytes and expressions of myocardin, transforming growth factor-beta, interleukin-6 and monocyte chemotactic protein 1.	ferric citrate	13-27	interleukin 6	Rattus norvegicus	141-154
30988246-10	2019	In addition, ferric citrate administration reduced the size of cardiomyocytes and expressions of myocardin, transforming growth factor-beta, interleukin-6 and monocyte chemotactic protein 1.	ferric citrate	13-27	C-C motif chemokine ligand 2	Rattus norvegicus	159-189
29181658-0	2018	Effect of ferric citrate hydrate on FGF23 and PTH levels in patients with non-dialysis-dependent chronic kidney disease with normophosphatemia and iron deficiency.	ferric citrate	10-24	fibroblast growth factor 23	Homo sapiens	36-41
29181658-4	2018	We hypothesized that ferric citrate hydrate, an iron-based phosphate binder, will decrease serum FGF23 levels in patients with non-dialysis-dependent CKD with normophosphatemia and iron deficiency.	ferric citrate	21-35	fibroblast growth factor 23	Homo sapiens	97-102
28642302-9	2017	To test this, iron uptake and intracellular reactive oxygen species were examined in HL-1 cardiomyocytes under conditions modeling transferrin effects on non-transferrin-bound iron speciation with ferric citrate.	ferric citrate	197-211	transferrin	Homo sapiens	131-142
30013785-8	2018	This is in contrast to the study by Lewis and colleagues, which found significant increases in ferritin and transferrin saturation levels in patients receiving ferric citrate versus active control (calcium acetate and/or sevelamer carbonate) after 52 weeks of therapy.	ferric citrate	160-174	transferrin	Homo sapiens	108-119
29988966-7	2018	The addition of iron (III) citrate restored HIF-1alpha hydroxylation and decreased total HIF-1alpha levels in PCa cells treated with CCA.	ferric citrate	16-34	hypoxia inducible factor 1 subunit alpha	Homo sapiens	44-54
29988966-7	2018	The addition of iron (III) citrate restored HIF-1alpha hydroxylation and decreased total HIF-1alpha levels in PCa cells treated with CCA.	ferric citrate	16-34	hypoxia inducible factor 1 subunit alpha	Homo sapiens	89-99
29682205-0	2018	Ferric citrate and ferric EDTA but not ferrous sulfate drive amphiregulin-mediated activation of the MAP kinase ERK in gut epithelial cancer cells.	ferric citrate	0-14	amphiregulin	Homo sapiens	61-73
29682205-0	2018	Ferric citrate and ferric EDTA but not ferrous sulfate drive amphiregulin-mediated activation of the MAP kinase ERK in gut epithelial cancer cells.	ferric citrate	0-14	mitogen-activated protein kinase 1	Homo sapiens	112-115
29682205-4	2018	Ferric EDTA and ferric citrate increased cellular levels of the onco-protein amphiregulin and its receptor (EGFr) which in turn stimulated the activation of the MAP kinase ERK.	ferric citrate	16-30	amphiregulin	Homo sapiens	77-89
29682205-4	2018	Ferric EDTA and ferric citrate increased cellular levels of the onco-protein amphiregulin and its receptor (EGFr) which in turn stimulated the activation of the MAP kinase ERK.	ferric citrate	16-30	epidermal growth factor receptor	Homo sapiens	108-112
29682205-4	2018	Ferric EDTA and ferric citrate increased cellular levels of the onco-protein amphiregulin and its receptor (EGFr) which in turn stimulated the activation of the MAP kinase ERK.	ferric citrate	16-30	mitogen-activated protein kinase 1	Homo sapiens	172-175
29682205-5	2018	Simultaneously, the expression of the negative Wnt regulator, DKK-1, increased suggesting that cell proliferation through the Wnt pathway may be less pronounced in the presence of ferric EDTA and ferric citrate, unlike for ferrous sulfate.	ferric citrate	196-210	dickkopf WNT signaling pathway inhibitor 1	Homo sapiens	62-67
29874654-0	2018	Ferric Citrate Decreases Fibroblast Growth Factor 23 and Improves Erythropoietin Responsiveness in Hemodialysis Patients.	ferric citrate	0-14	fibroblast growth factor 23	Homo sapiens	25-52
29874654-0	2018	Ferric Citrate Decreases Fibroblast Growth Factor 23 and Improves Erythropoietin Responsiveness in Hemodialysis Patients.	ferric citrate	0-14	erythropoietin	Homo sapiens	66-80
29874654-2	2018	The aim of the present study was to elucidate the effects of ferric citrate hydrate and lanthanum carbohydrate on serum FGF23 levels in hemodialysis patients.	ferric citrate	61-83	fibroblast growth factor 23	Homo sapiens	120-125
29874654-7	2018	RESULTS: FGF-23 levels were significantly lower in the ferric citrate group compared with the levels in the control group (change from baseline -6,160 vs. -1,118 pg/mL; p = 0.026).	ferric citrate	55-69	fibroblast growth factor 23	Homo sapiens	9-15
29874654-9	2018	The ferric citrate group had significantly increased serum iron, ferritin, and transferrin saturation.	ferric citrate	4-18	transferrin	Homo sapiens	79-90
29874654-12	2018	CONCLUSION: In patients on hemodialysis, 24-week treatment with ferric citrate hydrate resulted in significant reduction in FGF23 and ERI independently of serum phosphate level.	ferric citrate	64-86	fibroblast growth factor 23	Homo sapiens	124-129
29064631-0	2018	Ferric Citrate Supplementation Reduces Red-Blood-Cell Aggregation and Improves CD163+ Macrophage-Mediated Hemoglobin Metabolism in a Rat Model of High-Fat-Diet-Induced Obesity.	ferric citrate	0-14	CD163 molecule	Rattus norvegicus	79-84
29064631-9	2018	CONCLUSIONS: Ferric citrate supplementation reduces RBC aggregation and improves CD163+ macrophage-mediated Hb metabolism in HFD-induced obese rats.	ferric citrate	13-27	CD163 molecule	Rattus norvegicus	81-86
29291028-9	2017	Furthermore, ferric citrate significantly improved hemoglobin, transferrin saturation and ferritin.	ferric citrate	13-27	transferrin	Homo sapiens	63-74
27862990-6	2017	Ferric citrate supplementation showed a dose-related effect on the hepatic steatosis score, malondialdehyde, cathepsin D, and glyoxalase I.	ferric citrate	0-14	cathepsin D	Rattus norvegicus	109-120
27862990-6	2017	Ferric citrate supplementation showed a dose-related effect on the hepatic steatosis score, malondialdehyde, cathepsin D, and glyoxalase I.	ferric citrate	0-14	glyoxalase 1	Rattus norvegicus	126-138
26929139-6	2016	However, we found that, by supplementing the cell culture medium with ferric citrate, a comparable degree of iron uptake and MR contrast could be achieved in control cells that did not express the TfR1 transgene.	ferric citrate	70-84	transferrin receptor	Gallus gallus	197-201
29142965-14	2017	Discussion: It is suggested that not only iron load but also the erythropoiesis-stimulating agent dose reduction may be involved in ferritin elevation during ferric citrate hydrate treatment, resulting in a decrease of erythropoietin resistance index.	ferric citrate	158-172	erythropoietin	Homo sapiens	219-233
26616335-5	2016	Unlike conventional oral iron preparations, ferric citrate has recently been shown to be effective in increasing serum ferritin, hemoglobin, and transferrin saturation values while significantly reducing IV iron and ESA requirements in patients treated with HD.	ferric citrate	44-58	transferrin	Homo sapiens	145-156
23286295-6	2013	Also, to compare the capacities of our two maize hybrid varieties to deliver Fe for hemoglobin (Hb) synthesis and to improve the Fe status of Fe deficient broiler chickens.	ferric citrate	77-79	non-symbiotic hemoglobin	Zea mays	84-94
26813504-6	2016	In patients with nondialysis-dependent CKD, treatment with ferric citrate hydrate resulted in significant reductions in serum phosphate and FGF23.	ferric citrate	59-73	fibroblast growth factor 23	Homo sapiens	140-145
25468387-9	2015	Ferric citrate increased hemoglobin levels (from 10.5 +- 0.8 to 11.0 +- 1.0 g/dL; P<0.001 vs placebo), reduced urinary phosphate excretion 39% (P<0.001 vs placebo), and reduced serum intact FGF-23 levels from a median of 159 (IQR, 102-289) to 105 (IQR, 65-187) pg/mL (P=0.02 vs placebo).	ferric citrate	0-14	fibroblast growth factor 23	Homo sapiens	196-202
25468387-12	2015	CONCLUSIONS: Short-term use of ferric citrate repletes iron stores, increases hemoglobin levels, and reduces levels of serum phosphate, urinary phosphate excretion, and FGF-23 in patients with chronic kidney disease stages 3 to 5.	ferric citrate	31-45	fibroblast growth factor 23	Homo sapiens	169-175
26551233-0	2015	Administration of Ferric Citrate Hydrate Decreases Circulating FGF23 Levels Independently of Serum Phosphate Levels in Hemodialysis Patients with Iron Deficiency.	ferric citrate	18-32	fibroblast growth factor 23	Homo sapiens	63-68
26551233-10	2015	CONCLUSIONS: Oral FCH administration decreased serum intact FGF23 and C-term FGF23 levels and increased intact PTH levels; phosphate and 1,25(OH)2D levels were unchanged.	ferric citrate	18-21	fibroblast growth factor 23	Homo sapiens	60-65
26551233-10	2015	CONCLUSIONS: Oral FCH administration decreased serum intact FGF23 and C-term FGF23 levels and increased intact PTH levels; phosphate and 1,25(OH)2D levels were unchanged.	ferric citrate	18-21	fibroblast growth factor 23	Homo sapiens	77-82
26551233-11	2015	Oral FCH administration to treat iron deficiency is a possible strategy for reducing serum FGF23 levels independent of phosphate and VDRA.	ferric citrate	5-8	fibroblast growth factor 23	Homo sapiens	91-96
25158131-7	2014	Finally, when the HeLa cells overexpressing frataxin were treated with 5-aminolevulinic acid (ALA), there was less accumulation of protoporphyrin than HeLa control cells, and it was sharply decreased by the addition of iron citrate, suggesting that the utilization of mitochondrial iron for heme biosynthesis can be dependent on the level of frataxin.	ferric citrate	219-231	frataxin	Homo sapiens	44-52
25158131-7	2014	Finally, when the HeLa cells overexpressing frataxin were treated with 5-aminolevulinic acid (ALA), there was less accumulation of protoporphyrin than HeLa control cells, and it was sharply decreased by the addition of iron citrate, suggesting that the utilization of mitochondrial iron for heme biosynthesis can be dependent on the level of frataxin.	ferric citrate	219-231	frataxin	Homo sapiens	342-350
26611621-6	2016	Ferric citrate supplementation showed a dose-related effect on hepatic ER stress responses and total iron levels, which were associated with increased hepcidin and decreased ferroportin expressions.	ferric citrate	0-14	hepcidin antimicrobial peptide	Rattus norvegicus	151-159
25958079-12	2015	Parathyroid hormone levels decreased similarly in the ferric citrate and active control groups (-167.1+-399.8 vs -152.7+-392.1 pg/mL; P=0.8).	ferric citrate	54-68	parathyroid hormone	Homo sapiens	0-19
25060056-8	2015	Subjects on ferric citrate achieved higher mean iron parameters (ferritin=899+-488 ng/ml [mean+-SD]; transferrin saturation=39%+-17%) versus subjects on active control (ferritin=628+-367 ng/ml [mean+-SD]; transferrin saturation=30%+-12%; P<0.001 for both).	ferric citrate	12-26	transferrin	Homo sapiens	101-112
25060056-8	2015	Subjects on ferric citrate achieved higher mean iron parameters (ferritin=899+-488 ng/ml [mean+-SD]; transferrin saturation=39%+-17%) versus subjects on active control (ferritin=628+-367 ng/ml [mean+-SD]; transferrin saturation=30%+-12%; P<0.001 for both).	ferric citrate	12-26	transferrin	Homo sapiens	205-216
25060056-9	2015	Subjects on ferric citrate received less intravenous elemental iron (median=12.95 mg/wk ferric citrate; 26.88 mg/wk active control; P<0.001) and less erythropoietin-stimulating agent (median epoetin-equivalent units per week: 5306 units/wk ferric citrate; 6951 units/wk active control; P=0.04).	ferric citrate	12-26	erythropoietin	Homo sapiens	194-201
26551233-10	2015	CONCLUSIONS: Oral FCH administration decreased serum intact FGF23 and C-term FGF23 levels and increased intact PTH levels; phosphate and 1,25(OH)2D levels were unchanged.	ferric citrate	18-21	parathyroid hormone	Homo sapiens	111-114
25832833-6	2015	Moreover, in one clinical trial, ferric citrate hydrate significantly decreased levels of fibroblast growth factor-23 (FGF-23) in nondialysis patients.	ferric citrate	33-47	fibroblast growth factor 23	Homo sapiens	90-117
25832833-6	2015	Moreover, in one clinical trial, ferric citrate hydrate significantly decreased levels of fibroblast growth factor-23 (FGF-23) in nondialysis patients.	ferric citrate	33-47	fibroblast growth factor 23	Homo sapiens	119-125
25832833-8	2015	A portion of the iron from ferric citrate hydrate is absorbed and transported throughout the body as transferrin-bound iron, where it is used for the synthesis of hemoglobin, enzymes, and others.	ferric citrate	27-41	transferrin	Homo sapiens	101-112
25257695-5	2014	Serum biochemistry demonstrated increased iron and decreased total protein and transferrin in both sexes treated with 4.0% ferric citrate.	ferric citrate	123-137	transferrin	Rattus norvegicus	79-90
25242077-3	2014	Additionally, these studies demonstrate that ferric citrate improves iron parameters and reduces IV iron and erythropoietin stimulating agent utilization while maintaining hemoglobin levels.	ferric citrate	45-59	erythropoietin	Homo sapiens	109-123
24408120-8	2014	Fibroblast growth factor-23 concentrations were significantly lower in patients treated with ferric citrate hydrate versus placebo (change from baseline [median], -142.0 versus 67.0 pg/ml; P<0.001).	ferric citrate	93-115	fibroblast growth factor 23	Homo sapiens	0-27
24408120-9	2014	Ferric citrate hydrate significantly increased serum iron, ferritin, and transferrin saturation compared with placebo (P=0.001 or P<0.001).	ferric citrate	0-14	transferrin	Homo sapiens	73-84
24408120-12	2014	CONCLUSION: In patients with nondialysis-dependent CKD, 12-week treatment with ferric citrate hydrate resulted in significant reductions in serum phosphate and fibroblast growth factor-23 while simultaneously increasing serum iron parameters.	ferric citrate	79-93	fibroblast growth factor 23	Homo sapiens	160-187
22333152-2	2011	METHODS: The model was established by adding different concentrations (50, 100, 200, 400 micromol/L)of ferric citrate (FAC) into mononuclear cells from UCB and culturing for different times (6, 12, 24 h).	ferric citrate	103-117	FA complementation group C	Homo sapiens	119-122
22363330-5	2012	We demonstrate that of the additional three mtrB paralogs found in the S. oneidensis genome, only MtrE can replace MtrB to form a functional respiratory pathway to soluble iron(III) citrate.	ferric citrate	172-189	MtrB/PioB family decaheme-associated outer membrane protein	Shewanella oneidensis MR-1	44-48
22363330-5	2012	We demonstrate that of the additional three mtrB paralogs found in the S. oneidensis genome, only MtrE can replace MtrB to form a functional respiratory pathway to soluble iron(III) citrate.	ferric citrate	172-189	MtrB/PioB family decaheme-associated outer membrane protein	Shewanella oneidensis MR-1	115-119
22699086-6	2012	Compared with cells treated with ethanol alone, ferric citrate enhanced the accumulation of reactive oxygen and nitrogen species, increased the occurrence of protein carbonylation/nitration and the levels of 4-hydroxy-2-nonenal, changed the distribution of iNOS, and eventually resulted in apoptosis.	ferric citrate	48-62	inositol-3-phosphate synthase 1	Homo sapiens	257-261
20519508-5	2010	In vitro and in vivo inhibition of PTP activity by iron-citrate results in protein hyperphosphorylation and enhanced MAPK signaling in response to LPS stimulation.	ferric citrate	51-63	protein tyrosine phosphatase non-receptor type 22	Homo sapiens	35-38
22373384-0	2011	Characterization of metalloprotease and serine protease activities in batch CHO cell cultures: control of human recombinant IFN-gamma proteolysis by addition of iron citrate.	ferric citrate	161-173	interferon gamma	Homo sapiens	124-133
22338154-2	2011	METHODS: BM mononuclear cells (BMMNCs) were cultured with ferric citrate (FAC) at different concentrations and for different time to create iron overload and confirmed by the detection of cellular labile iron pool (LIP).	ferric citrate	58-72	FA complementation group C	Homo sapiens	74-77
21867640-2	2011	The iron overload model was set up by adding different concentration of ferric citrate (FAC) into the mononuclear cells from BM and culturing for different time, and the model was confirmed by detecting labile iron pool (LIP).	ferric citrate	72-86	FA complementation group C	Homo sapiens	88-91
21483602-4	2011	Magnetic resonance imaging of tyrosinase-expressing MCF-7 cells in 300 muL plastic tubes displayed a 34 to 40% reduction in T1 compared to normal MCF-7 cells when cells were incubated with 250 muM ferric citrate.	ferric citrate	197-211	tyrosinase	Homo sapiens	30-40
20519508-6	2010	We propose that iron-citrate-mediated PTP inhibition represents a novel and biologically relevant regulatory mechanism of signal transduction.	ferric citrate	16-28	protein tyrosine phosphatase non-receptor type 22	Homo sapiens	38-41
19264360-0	2009	Efficiency of methemoglobin, hemin and ferric citrate in catalyzing protein tyrosine nitration, protein oxidation and lipid peroxidation in a bovine serum albumin-liposome system: influence of pH.	ferric citrate	39-53	albumin	Homo sapiens	149-162
15731565-7	2005	Desferrioxamine, an iron chelator, eliminated the suppressive effect of ferric citrate on TGF-beta1 production.	ferric citrate	72-86	transforming growth factor beta 1	Homo sapiens	90-99
16950869-6	2006	Addition of bathophenanthroline sulfonate, a cell-impermeant ferrous iron chelator, inhibited Zip14-mediated iron uptake from ferric citrate, suggesting that iron is taken up by HEK cells as Fe(2+).	ferric citrate	126-140	solute carrier family 39 member 14	Homo sapiens	94-99
16527254-6	2006	DFX-induced increase of COX-2 expression and HIF-1alpha protein level was attenuated by addition of ferric citrate.	ferric citrate	100-114	prostaglandin-endoperoxide synthase 2	Homo sapiens	24-29
16527254-6	2006	DFX-induced increase of COX-2 expression and HIF-1alpha protein level was attenuated by addition of ferric citrate.	ferric citrate	100-114	hypoxia inducible factor 1 subunit alpha	Homo sapiens	45-55
18278581-1	2008	We have shown previously that iron deprivation significantly stimulates the uptake of non-transferrin ferric iron from ferric citrate by erythroleukemia K562 cells and that this stimulation depends on protein synthesis.	ferric citrate	119-133	transferrin	Homo sapiens	90-101
17351051-13	2007	These results all strongly support the hypothesis that FRD3 effluxes citrate into the root vasculature, a process important for the translocation of iron to the leaves, as well as confirm previous reports suggesting that iron moves through the xylem as a ferric-citrate complex.	ferric citrate	255-269	MATE efflux family protein	Arabidopsis thaliana	55-59
17015257-1	2006	The addition of ferric citrate to Burkitt"s lymphoma (BL) cell lines inhibits growth, leads to the accumulation of cells in the phase G(2)/M of the cell cycle and to the modulation of translocated c-myc expression.	ferric citrate	16-30	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	197-202
14603992-10	2003	Using flow cytometry analysis, the co-addition of Fe-citrate significantly suppressed CD18 (beta2 integrin) and CD54 (ICAM-I) but not CD11a (alpha integrin) expression on Con A-stimulated monocytes.	ferric citrate	50-60	integrin subunit beta 2	Homo sapiens	86-90
15935835-3	2005	Co-treatment with ferric citrate quenched the effect of deferoxamine, confirming the role of iron in PAI-1 regulation.	ferric citrate	18-32	serpin family E member 1	Homo sapiens	101-106
15155457-5	2004	Total ferric citrate uptake by hepatocytes isolated from Hfe knockout mice (34.1 +/- 2.8 pmol Fe/mg protein/min) increased by 2-fold compared with control mice (17.8 +/- 2.7 pmol Fe/mg protein/min; P <.001; mean +/- SEM; n = 7).	ferric citrate	6-20	homeostatic iron regulator	Mus musculus	57-60
14603992-10	2003	Using flow cytometry analysis, the co-addition of Fe-citrate significantly suppressed CD18 (beta2 integrin) and CD54 (ICAM-I) but not CD11a (alpha integrin) expression on Con A-stimulated monocytes.	ferric citrate	50-60	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	92-97
14603992-10	2003	Using flow cytometry analysis, the co-addition of Fe-citrate significantly suppressed CD18 (beta2 integrin) and CD54 (ICAM-I) but not CD11a (alpha integrin) expression on Con A-stimulated monocytes.	ferric citrate	50-60	intercellular adhesion molecule 1	Homo sapiens	112-116
12393231-2	2002	In this study we found that both neurotrophin-4 (NT-4) and basic fibroblast growth factor (bFGF) potentiated necrotic neuronal death caused by exposure to oxygen-glucose deprivation or iron-citrate (Fe) in cortical cultures.	ferric citrate	185-197	neurotrophin 4	Homo sapiens	33-47
12716026-3	2003	Treatment with fibroblast growth factor-2, neurotrophin-4, or insulin-like growth factor-1 potentiated neuronal cell death induced by iron-citrate (Fe) or buthionine sulfoximine (BSO), but not ethacrynic acid (EA).	ferric citrate	134-146	fibroblast growth factor 2	Homo sapiens	15-41
12716026-3	2003	Treatment with fibroblast growth factor-2, neurotrophin-4, or insulin-like growth factor-1 potentiated neuronal cell death induced by iron-citrate (Fe) or buthionine sulfoximine (BSO), but not ethacrynic acid (EA).	ferric citrate	134-146	neurotrophin 4	Homo sapiens	43-57
12716026-3	2003	Treatment with fibroblast growth factor-2, neurotrophin-4, or insulin-like growth factor-1 potentiated neuronal cell death induced by iron-citrate (Fe) or buthionine sulfoximine (BSO), but not ethacrynic acid (EA).	ferric citrate	134-146	insulin like growth factor 1	Homo sapiens	62-90
12393231-2	2002	In this study we found that both neurotrophin-4 (NT-4) and basic fibroblast growth factor (bFGF) potentiated necrotic neuronal death caused by exposure to oxygen-glucose deprivation or iron-citrate (Fe) in cortical cultures.	ferric citrate	185-197	neurotrophin 4	Homo sapiens	49-53
12393231-2	2002	In this study we found that both neurotrophin-4 (NT-4) and basic fibroblast growth factor (bFGF) potentiated necrotic neuronal death caused by exposure to oxygen-glucose deprivation or iron-citrate (Fe) in cortical cultures.	ferric citrate	185-197	fibroblast growth factor 2	Homo sapiens	59-89
12393231-2	2002	In this study we found that both neurotrophin-4 (NT-4) and basic fibroblast growth factor (bFGF) potentiated necrotic neuronal death caused by exposure to oxygen-glucose deprivation or iron-citrate (Fe) in cortical cultures.	ferric citrate	185-197	fibroblast growth factor 2	Homo sapiens	91-95
11241357-4	2001	In the presence of DF, PMA-induced upregulation of the cyclin dependent kinase inhibitor (CDKI), p21(WAF1/CIP1), was blocked and its expression could be restored in the presence of DF by supplementation with ferric citrate.	ferric citrate	208-222	cyclin dependent kinase inhibitor 3	Homo sapiens	55-88
12130502-10	2002	HSFC proliferation was increased in a dose-dependent fashion and c-myc expression was enhanced by ferric citrate compared to sodium citrate control.	ferric citrate	98-112	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	65-70
11755321-6	2002	Moreover an acute exposure of primary cultures of mouse hepatocytes to iron-citrate strongly induced oxidative stress and cellular injury and resulted in an increase in GSTA4 expression, while cotreatment with iron-citrate and either desferrioxamine or vitamin E prevented both toxicity and GSTA4 induction.	ferric citrate	71-83	glutathione S-transferase, alpha 4	Mus musculus	169-174
11755321-6	2002	Moreover an acute exposure of primary cultures of mouse hepatocytes to iron-citrate strongly induced oxidative stress and cellular injury and resulted in an increase in GSTA4 expression, while cotreatment with iron-citrate and either desferrioxamine or vitamin E prevented both toxicity and GSTA4 induction.	ferric citrate	71-83	glutathione S-transferase, alpha 4	Mus musculus	291-296
11755321-6	2002	Moreover an acute exposure of primary cultures of mouse hepatocytes to iron-citrate strongly induced oxidative stress and cellular injury and resulted in an increase in GSTA4 expression, while cotreatment with iron-citrate and either desferrioxamine or vitamin E prevented both toxicity and GSTA4 induction.	ferric citrate	210-222	glutathione S-transferase, alpha 4	Mus musculus	291-296
11241357-4	2001	In the presence of DF, PMA-induced upregulation of the cyclin dependent kinase inhibitor (CDKI), p21(WAF1/CIP1), was blocked and its expression could be restored in the presence of DF by supplementation with ferric citrate.	ferric citrate	208-222	cyclin dependent kinase inhibitor 3	Homo sapiens	90-94
11241357-4	2001	In the presence of DF, PMA-induced upregulation of the cyclin dependent kinase inhibitor (CDKI), p21(WAF1/CIP1), was blocked and its expression could be restored in the presence of DF by supplementation with ferric citrate.	ferric citrate	208-222	cyclin dependent kinase inhibitor 1A	Homo sapiens	97-100
11241357-4	2001	In the presence of DF, PMA-induced upregulation of the cyclin dependent kinase inhibitor (CDKI), p21(WAF1/CIP1), was blocked and its expression could be restored in the presence of DF by supplementation with ferric citrate.	ferric citrate	208-222	cyclin dependent kinase inhibitor 1A	Homo sapiens	101-105
11241357-4	2001	In the presence of DF, PMA-induced upregulation of the cyclin dependent kinase inhibitor (CDKI), p21(WAF1/CIP1), was blocked and its expression could be restored in the presence of DF by supplementation with ferric citrate.	ferric citrate	208-222	cyclin dependent kinase inhibitor 1A	Homo sapiens	106-110
9545519-0	1998	Characterisation of non-transferrin-bound iron (ferric citrate) uptake by rat hepatocytes in culture.	ferric citrate	48-62	transferrin	Rattus norvegicus	24-35
10748212-7	2000	Maximum ferritin derepression was obtained with 50 microm iron citrate (1:10) or 500 microm iron citrate (1:1) but Fe-EDTA was ineffective, although the leaf iron concentration was increased; manganese, zinc, and copper had no effect.	ferric citrate	58-70	ferritin-1, chloroplastic	Glycine max	8-16
10748212-7	2000	Maximum ferritin derepression was obtained with 50 microm iron citrate (1:10) or 500 microm iron citrate (1:1) but Fe-EDTA was ineffective, although the leaf iron concentration was increased; manganese, zinc, and copper had no effect.	ferric citrate	92-104	ferritin-1, chloroplastic	Glycine max	8-16
10813095-4	2000	However, the rate of iron uptake from 55Fe-ferric citrate by PI-PLC-treated HeLa cells was comparable or only slightly lower (80-100%) than the rate of iron uptake by untreated cells.	ferric citrate	43-57	phospholipase C beta 1	Homo sapiens	61-67
9714298-5	1998	The protective effect of O-Trensox against iron toxicity induced in hepatocyte cultures by ferric citrate was shown by decreased release of the enzymes lactate dehydrogenase (LDH), aspartate aminotransferase (AST), and alanine aminotranferase (ALT) from the cultures and, using electron paramagnetic resonance (EPR) measurements, decreased production of lipid radicals.	ferric citrate	91-105	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	181-207
9714298-5	1998	The protective effect of O-Trensox against iron toxicity induced in hepatocyte cultures by ferric citrate was shown by decreased release of the enzymes lactate dehydrogenase (LDH), aspartate aminotransferase (AST), and alanine aminotranferase (ALT) from the cultures and, using electron paramagnetic resonance (EPR) measurements, decreased production of lipid radicals.	ferric citrate	91-105	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	209-212
9626590-4	1998	On a per nanomole cytochrome P450 basis, CYP3A4 was the most active P450 evaluated in catalyzing NADPH oxidation, production of superoxide anion radical, NADPH-dependent chemiluminescence, oxidation of dichlorofluorescein diacetate, and reduction of either ferric-EDTA or ferric-citrate.	ferric citrate	272-286	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	41-47
10772765-5	2000	In HepG2 cells, normalized(35)S-metabolically labeled transferrin synthesis was consistently less following iron treatment with hemin or ferric citrate, than following treatment with an iron-chelator deferroxamine.	ferric citrate	137-151	transferrin	Homo sapiens	54-65
10070275-7	1998	Fe-citrate inhibited the spontaneous PGE2 production by the cells in a dose dependent manner, and a maximum inhibition by Fe-citrate was observed at the concentration of 0.1 mM with IL1 beta stimulation.	ferric citrate	0-10	interleukin 1 beta	Homo sapiens	182-190
10070275-7	1998	Fe-citrate inhibited the spontaneous PGE2 production by the cells in a dose dependent manner, and a maximum inhibition by Fe-citrate was observed at the concentration of 0.1 mM with IL1 beta stimulation.	ferric citrate	122-132	interleukin 1 beta	Homo sapiens	182-190
9578471-0	1998	Ferric citrate uptake by cultured rat hepatocytes is inhibited in the presence of transferrin.	ferric citrate	0-14	transferrin	Rattus norvegicus	82-93
9578471-5	1998	This study was conducted to investigate the effects of transferrin on the uptake of citrate and iron citrate by hepatocytes in culture.	ferric citrate	96-108	transferrin	Rattus norvegicus	55-66
10730863-7	1998	We suggest that iron supplied as non-transferrin iron (ferric citrate) is apparently less available for the control of transferrin receptor expression via IRP activity than iron supplied as transferrin.	ferric citrate	55-69	transferrin	Homo sapiens	119-130
10730863-3	1998	Transferrin receptor expression of studied cell lines (HeLa, K562, Jiyoye) grown as long-term cultures in transferrin medium was somewhat higher (up to 137% of the mean fluorescence intensity) than in ferric citrate medium.	ferric citrate	201-215	transferrin	Homo sapiens	0-11
10730863-7	1998	We suggest that iron supplied as non-transferrin iron (ferric citrate) is apparently less available for the control of transferrin receptor expression via IRP activity than iron supplied as transferrin.	ferric citrate	55-69	Wnt family member 2	Homo sapiens	155-158
10730863-7	1998	We suggest that iron supplied as non-transferrin iron (ferric citrate) is apparently less available for the control of transferrin receptor expression via IRP activity than iron supplied as transferrin.	ferric citrate	55-69	transferrin	Homo sapiens	119-130
8840271-9	1996	We found that ferric citrate diminished proliferation and this decrease required the presence of either serum or transferrin.	ferric citrate	14-28	transferrin	Sus scrofa	113-124
9138275-4	1997	One day after iron treatment, an increase in AST, ALT and MDA release was observed with 50 or 100 microM of iron citrate; it appeared that the concentrations 50 and 100 microM of iron were highly toxic for human hepatocytes.	ferric citrate	108-120	solute carrier family 17 member 5	Homo sapiens	45-48
9812635-1	1997	Cell culture in vitro, ABC-ELISA,RNA dot blot and atom absorption spectrum analysis were used to study biological effects of low concentration of iron citrate (Fe-cit) on the expression of transferrin receptor (TfR) in healthy human peripheral lymphocytes.	ferric citrate	146-158	transferrin receptor	Homo sapiens	189-209
9812635-1	1997	Cell culture in vitro, ABC-ELISA,RNA dot blot and atom absorption spectrum analysis were used to study biological effects of low concentration of iron citrate (Fe-cit) on the expression of transferrin receptor (TfR) in healthy human peripheral lymphocytes.	ferric citrate	146-158	transferrin receptor	Homo sapiens	211-214
9303500-5	1997	Iron citrate inhibited the uptake of 59Fe-transferrin (2.5 micromol/L Fe) in a concentration-dependent manner with a maximum effect when the citrate-iron:Tf-Fe molar ratio was 10:1.	ferric citrate	0-12	transferrin	Homo sapiens	42-53
9303500-9	1997	Iron citrate did not affect the maximum rate (Vmax) of Tf-Fe uptake but the Michaelis-Menten constant (Km) for Tf-Fe uptake by the NTR-mediated process was increased, indicating there was competitive inhibition of Tf-Fe uptake by iron citrate.	ferric citrate	0-12	neurotensin receptor 1	Homo sapiens	131-134
9303500-9	1997	Iron citrate did not affect the maximum rate (Vmax) of Tf-Fe uptake but the Michaelis-Menten constant (Km) for Tf-Fe uptake by the NTR-mediated process was increased, indicating there was competitive inhibition of Tf-Fe uptake by iron citrate.	ferric citrate	230-242	neurotensin receptor 1	Homo sapiens	131-134
9089659-4	1997	Our new data of His6 and Phe7 substituted MSH peptides are compared with previous results and the hypothesis of putative interactions of D117 and H260 with single amino acids in the MSH peptide.	ferric citrate	146-150	proopiomelanocortin	Homo sapiens	42-45
9089659-4	1997	Our new data of His6 and Phe7 substituted MSH peptides are compared with previous results and the hypothesis of putative interactions of D117 and H260 with single amino acids in the MSH peptide.	ferric citrate	146-150	proopiomelanocortin	Homo sapiens	182-185
8528518-5	1995	However, we have also found that from 13 human cell lines tested, 4 were capable of long-term growth in transferrin-free medium with a substantially lower concentration of ferric citrate (5 microM).	ferric citrate	172-186	transferrin	Homo sapiens	104-115
8661930-3	1996	PAL-1 grew in a defined medium with acetate as electron donor and ferric pyrophosphate, ferric oxyhydroxide, ferric citrate, Co(III)-EDTA, or elemental sulfur as sole electron acceptor.	ferric citrate	109-123	Pal1p	Saccharomyces cerevisiae S288C	0-5
8528518-8	1995	On the contrary, growth of low-iron dependent cell lines in transferrin-free, low-iron medium (5 microM ferric citrate) could not be inhibited by monoclonal antibody 42/6.	ferric citrate	104-118	transferrin	Homo sapiens	60-71
8528518-11	1995	We conclude that low-iron dependent tumor cells in transferrin-free, low-iron medium may employ a previously unknown mechanism for uptake of non-transferrin-bound iron that allows them to efficiently use low concentrations of ferric citrate as an iron source.	ferric citrate	226-240	transferrin	Homo sapiens	51-62
8528518-11	1995	We conclude that low-iron dependent tumor cells in transferrin-free, low-iron medium may employ a previously unknown mechanism for uptake of non-transferrin-bound iron that allows them to efficiently use low concentrations of ferric citrate as an iron source.	ferric citrate	226-240	transferrin	Homo sapiens	145-156
7772844-2	1995	We evaluated various iron salts and chelating agents replacing transferrin to develop a protein-free medium for a human-human hybridoma, HB4C5, and found out that ferric citrate was favorable for the production and the productivity of monoclonal antibodies.	ferric citrate	163-177	transferrin	Homo sapiens	63-74
7499788-5	1995	The bidentate chelators CP20 and CP94 (150 microM) appeared to be as effective as the hexadentate chelator desferrioxamine (50 microM) in the protection of rat and human hepatocytes against the toxic effect of iron load achieved by culturing the cells for 1 day in the presence of 50 microM iron citrate.	ferric citrate	291-303	lymphocyte cytosolic protein, molecular weight 20kD	Homo sapiens	24-28
2150666-5	1990	At these same concentrations ferric citrate also produced significant reductions in the cloning frequency of CD4+ CD8-precursor T lymphocytes.	ferric citrate	29-43	CD4 molecule	Homo sapiens	109-112
7867079-3	1995	Ferric citrate was seen to differentially modulate the CD4-lck and CD8-lck complexes in resting peripheral blood T-lymphocytes (PBLs) cultured in the presence of this metal salt for periods of 20 to 24 hr.	ferric citrate	0-14	CD4 molecule	Homo sapiens	55-58
7867079-3	1995	Ferric citrate was seen to differentially modulate the CD4-lck and CD8-lck complexes in resting peripheral blood T-lymphocytes (PBLs) cultured in the presence of this metal salt for periods of 20 to 24 hr.	ferric citrate	0-14	LCK proto-oncogene, Src family tyrosine kinase	Homo sapiens	59-62
7867079-3	1995	Ferric citrate was seen to differentially modulate the CD4-lck and CD8-lck complexes in resting peripheral blood T-lymphocytes (PBLs) cultured in the presence of this metal salt for periods of 20 to 24 hr.	ferric citrate	0-14	CD8a molecule	Homo sapiens	67-70
7867079-3	1995	Ferric citrate was seen to differentially modulate the CD4-lck and CD8-lck complexes in resting peripheral blood T-lymphocytes (PBLs) cultured in the presence of this metal salt for periods of 20 to 24 hr.	ferric citrate	0-14	LCK proto-oncogene, Src family tyrosine kinase	Homo sapiens	71-74
7867079-4	1995	Thus, whereas ferric citrate invariably induced a marked decrease in the in vitro activity of the CD4-associated lck by three- to fourfold at 100 microM (P < 3 x 10(-5)), it did not affect significantly the in vitro activity of the CD8-associated lck, although modest decreases were observed in some experiments.	ferric citrate	14-28	CD4 molecule	Homo sapiens	98-101
7867079-4	1995	Thus, whereas ferric citrate invariably induced a marked decrease in the in vitro activity of the CD4-associated lck by three- to fourfold at 100 microM (P < 3 x 10(-5)), it did not affect significantly the in vitro activity of the CD8-associated lck, although modest decreases were observed in some experiments.	ferric citrate	14-28	LCK proto-oncogene, Src family tyrosine kinase	Homo sapiens	113-116
7867079-4	1995	Thus, whereas ferric citrate invariably induced a marked decrease in the in vitro activity of the CD4-associated lck by three- to fourfold at 100 microM (P < 3 x 10(-5)), it did not affect significantly the in vitro activity of the CD8-associated lck, although modest decreases were observed in some experiments.	ferric citrate	14-28	CD8a molecule	Homo sapiens	235-238
7867079-4	1995	Thus, whereas ferric citrate invariably induced a marked decrease in the in vitro activity of the CD4-associated lck by three- to fourfold at 100 microM (P < 3 x 10(-5)), it did not affect significantly the in vitro activity of the CD8-associated lck, although modest decreases were observed in some experiments.	ferric citrate	14-28	LCK proto-oncogene, Src family tyrosine kinase	Homo sapiens	250-253
7867079-5	1995	Immunoprecipitation and subsequent lck-immunoblotting revealed that the marked decrease in CD4-lck activity induced by 100 microM of ferric citrate was due to a decrease in the amount of p56lck on CD4 immunoprecipitates.	ferric citrate	133-147	LCK proto-oncogene, Src family tyrosine kinase	Homo sapiens	35-38
7867079-5	1995	Immunoprecipitation and subsequent lck-immunoblotting revealed that the marked decrease in CD4-lck activity induced by 100 microM of ferric citrate was due to a decrease in the amount of p56lck on CD4 immunoprecipitates.	ferric citrate	133-147	CD4 molecule	Homo sapiens	91-94
7867079-5	1995	Immunoprecipitation and subsequent lck-immunoblotting revealed that the marked decrease in CD4-lck activity induced by 100 microM of ferric citrate was due to a decrease in the amount of p56lck on CD4 immunoprecipitates.	ferric citrate	133-147	LCK proto-oncogene, Src family tyrosine kinase	Homo sapiens	95-98
7867079-5	1995	Immunoprecipitation and subsequent lck-immunoblotting revealed that the marked decrease in CD4-lck activity induced by 100 microM of ferric citrate was due to a decrease in the amount of p56lck on CD4 immunoprecipitates.	ferric citrate	133-147	LCK proto-oncogene, Src family tyrosine kinase	Homo sapiens	187-193
7867079-5	1995	Immunoprecipitation and subsequent lck-immunoblotting revealed that the marked decrease in CD4-lck activity induced by 100 microM of ferric citrate was due to a decrease in the amount of p56lck on CD4 immunoprecipitates.	ferric citrate	133-147	CD4 molecule	Homo sapiens	197-200
7867079-8	1995	This differential effect of ferric citrate on the CD4+ and CD8+ T-cell subsets led to a marked decrease in the CD4/CD8 ratios in iron-treated PBLs after the 20- to 24-hr period (P < 0.001).	ferric citrate	28-42	CD4 molecule	Homo sapiens	50-53
7867079-8	1995	This differential effect of ferric citrate on the CD4+ and CD8+ T-cell subsets led to a marked decrease in the CD4/CD8 ratios in iron-treated PBLs after the 20- to 24-hr period (P < 0.001).	ferric citrate	28-42	CD8a molecule	Homo sapiens	59-62
7867079-8	1995	This differential effect of ferric citrate on the CD4+ and CD8+ T-cell subsets led to a marked decrease in the CD4/CD8 ratios in iron-treated PBLs after the 20- to 24-hr period (P < 0.001).	ferric citrate	28-42	CD4 molecule	Homo sapiens	111-114
7867079-8	1995	This differential effect of ferric citrate on the CD4+ and CD8+ T-cell subsets led to a marked decrease in the CD4/CD8 ratios in iron-treated PBLs after the 20- to 24-hr period (P < 0.001).	ferric citrate	28-42	CD8a molecule	Homo sapiens	115-118
8144605-2	1994	Reconstitution of the H(+)-ATPase into liposomes was performed by sonicating a lipid mixture, with a composition similar to the reticulocyte plasma membrane, in a buffer containing ferric citrate.	ferric citrate	181-195	dynein axonemal heavy chain 8	Homo sapiens	27-33
8167581-0	1994	[Effects of pretreating target cells with iron citrate on cytolysis, mediated by tumor necrosis factor and lymphokine-activated killer cells].	ferric citrate	42-54	tumor necrosis factor	Homo sapiens	81-102
8167581-0	1994	[Effects of pretreating target cells with iron citrate on cytolysis, mediated by tumor necrosis factor and lymphokine-activated killer cells].	ferric citrate	42-54	interleukin 2	Homo sapiens	107-117
8406790-5	1993	In hemin-restricted media, transferrin binding occurred despite addition of up to 10 mM ferric nitrate, ferric citrate, or ferric PPi, whereas addition of 10 micrograms of hemoglobin ml-1 repressed expression.	ferric citrate	104-118	transferrin	Homo sapiens	27-38
2264818-1	1990	Ferric citrate induces ferritin synthesis and accumulation in soybean (Glycine max) cell suspension cultures [Proudhon, Briat & Lescure (1989) Plant Physiol.	ferric citrate	0-14	ferritin-1, chloroplastic	Glycine max	23-31
2264818-3	1990	This iron-induced ferritin has been purified from cells grown for 72 h in the presence of either 100 microM- or 500 microM-ferric citrate.	ferric citrate	123-137	ferritin-1, chloroplastic	Glycine max	18-26
2264818-6	1990	It is shown that the presence of 100 microM- or 500 microM-ferric citrate in the culture medium leads respectively to an 11- and 28-fold increase in the total intracellular iron concentration and to a 30- and 60-fold increase in the ferritin concentration.	ferric citrate	59-73	ferritin-1, chloroplastic	Glycine max	233-241
2264818-7	1990	However, the percentage of iron stored in the mineral core of ferritin remains constant whatever the ferric citrate concentration used and represents only 5-6% of cellular iron.	ferric citrate	101-115	ferritin-1, chloroplastic	Glycine max	62-70
7945215-1	1994	Mammalian cells accumulate iron from ferric citrate or ferric nitrilotriacetate through the activity of a transferrin-independent iron transport system [Sturrock, Alexander, Lamb, Craven and Kaplan (1990) J. Biol.	ferric citrate	37-51	transferrin	Homo sapiens	106-117
7764121-3	1993	On the basis of medium SFM II, the substitution tests of ferric citrate for transferrin were carried out, and it was found that transferrin could be replaced.	ferric citrate	57-71	transferrin	Homo sapiens	128-139
1568866-2	1992	This study confirms and extends those observations by showing that iron citrate inhibits the mitogen-induced (PHA, Con A and PWM) lymphocyte proliferation.	ferric citrate	67-79	lamin B receptor	Homo sapiens	110-113
2208657-7	1990	Transferrin-bound iron is determined by applying diluted serum without added ferric citrate to an alumina column and measuring the iron in the column eluate.	ferric citrate	77-91	transferrin	Homo sapiens	0-11
2208657-9	1990	Using this method, we found that transferrin iron-binding sites are saturated in vitro by excess iron-dextran less efficiently than by ferric citrate.	ferric citrate	135-149	transferrin	Homo sapiens	33-44
2393846-4	1990	Monoclonal antibody to the transferrin receptor significantly decreased the growth inhibiting effect of transferrin-gallium in the mouse ferric citrate system.	ferric citrate	137-151	transferrin	Mus musculus	27-38
2393846-4	1990	Monoclonal antibody to the transferrin receptor significantly decreased the growth inhibiting effect of transferrin-gallium in the mouse ferric citrate system.	ferric citrate	137-151	transferrin	Mus musculus	104-115
2150666-5	1990	At these same concentrations ferric citrate also produced significant reductions in the cloning frequency of CD4+ CD8-precursor T lymphocytes.	ferric citrate	29-43	CD8a molecule	Homo sapiens	114-117
32470149-8	2021	These led to significant reductions in calcium-phosphorus product with ferric citrate versus no active control (SMD=-1.02; p<0.001) but no difference versus active control (SMD=-0.01; p=0.93).	ferric citrate	71-85	small nuclear ribonucleoprotein D1 polypeptide	Homo sapiens	112-118
34787162-8	2021	In conclusion, obese rats that received high-dose ferric citrate supplementation (>1 g of ferric iron per kg diet) exhibited decreased n-3 PUFA levels via downregulation of expressions of Delta5 and Delta6 desaturase enzymes.	ferric citrate	50-64	fatty acid desaturase 2	Rattus norvegicus	205-216
35237863-6	2022	Clinical trials in adult CKD cohorts have also demonstrated that ferric citrate decreases circulating FGF23 concentrations.	ferric citrate	65-79	fibroblast growth factor 23	Homo sapiens	102-107
2524277-3	1989	Transferrin saturation peaked (88-95%) 1 hr post-Fe-cit and returned to baseline values within 24 hr.	ferric citrate	49-55	transferrin	Rattus norvegicus	0-11
6421970-9	1984	Because the amidolytic activity of human thrombin as well as factor Xa, kallikrein, and bovine trypsin was also reversibly suppressed by ferrous sulfate as well as ferric citrate, we consider it likely that the coagulopathy occurring in iron poisoning is the consequence of a general, physiologically important phenomenon: the susceptibility of serine proteases to nontransferrin-bound Fe3+.	ferric citrate	164-178	coagulation factor II, thrombin	Homo sapiens	41-49
6421970-9	1984	Because the amidolytic activity of human thrombin as well as factor Xa, kallikrein, and bovine trypsin was also reversibly suppressed by ferrous sulfate as well as ferric citrate, we consider it likely that the coagulopathy occurring in iron poisoning is the consequence of a general, physiologically important phenomenon: the susceptibility of serine proteases to nontransferrin-bound Fe3+.	ferric citrate	164-178	coagulation factor X	Homo sapiens	61-70
6421970-9	1984	Because the amidolytic activity of human thrombin as well as factor Xa, kallikrein, and bovine trypsin was also reversibly suppressed by ferrous sulfate as well as ferric citrate, we consider it likely that the coagulopathy occurring in iron poisoning is the consequence of a general, physiologically important phenomenon: the susceptibility of serine proteases to nontransferrin-bound Fe3+.	ferric citrate	164-178	kallikrein related peptidase 4	Homo sapiens	72-82
34122381-0	2021	The Ferric Citrate Uptake System Encoded in a Novel bla CTX-M-3- and bla TEM-1-Harboring Conjugative Plasmid Contributes to the Virulence of Escherichia coli.	ferric citrate	4-18	hypothetical protein	Escherichia coli	73-78
35461329-3	2022	As expected, ferric citrate lowered serum phosphate concentrations and increased serum iron levels in the Col4alpha3 knockout mice.	ferric citrate	13-27	collagen, type IV, alpha 3	Mus musculus	106-116
35461329-4	2022	Consistent with decreased enteral phosphate absorption and possibly improved iron status, ferric citrate greatly reduced circulating fibroblast growth factor 23 levels.	ferric citrate	90-104	fibroblast growth factor 23	Mus musculus	133-160
2556968-6	1989	NADH-dependent .OH production was effectively catalyzed by ferric-EDTA and ferric-diethylenetriaminepentaacetic acid (DTPA), whereas ferric-ATP and ferric-citrate were poor catalysts.	ferric citrate	148-162	2,4-dienoyl-CoA reductase 1	Homo sapiens	0-4
2721585-4	1989	Cultivation of the cells at the optimum growth-stimulating concentration (500 microM) of ferric citrate resulted in an intracellular iron level about 100-fold higher than that of cells cultivated at the optimum transferrin concentration (5 micrograms/ml).	ferric citrate	89-103	serotransferrin	Bos taurus	211-222
3397072-0	1988	Growth-stimulating effect of ferric citrate on hybridoma cells: characterization and relation to transferrin function.	ferric citrate	29-43	transferrin	Mus musculus	97-108
3397072-2	1988	Experiments with monoclonal antibody to mouse transferrin receptor demonstrate that the growth-stimulating effect of ferric citrate is not based on the action of residual transferrin or the action of transferrin secreted by hybridoma cells.	ferric citrate	117-131	transferrin	Mus musculus	46-57
3377869-1	1988	We observed a consistent sequence of activation changes in rat knee synovia following a single intravenous injection of sterile ferric citrate at a dosage sufficient to cause a transient saturation of transferrin.	ferric citrate	128-142	transferrin	Rattus norvegicus	201-212
32470149-6	2021	Phosphate-lowering effects of ferric citrate were greater compared to no active treatment (SMD=-1.15; p<0.001) and comparable to other phosphate binders (SMD=0.03; p=0.61).	ferric citrate	30-44	small nuclear ribonucleoprotein D1 polypeptide	Homo sapiens	91-97
32514572-2	2020	However, phosphate binder, ferric citrate (FC) overcomes the CKD-induced impairment of iron absorption and increases serum iron, transferrin saturation, and iron stores and reduces erythropoietin requirements in CKD/ESRD patients.	ferric citrate	27-41	transferrin	Homo sapiens	129-140
32694162-8	2020	Similarly, as compared with ferrous sulfate, treatment with ferric citrate resulted in a greater increase in hepcidin from baseline to 12 weeks (between-group difference, 69 pg/ml; 95% CI, 8 to 130).	ferric citrate	60-74	hepcidin antimicrobial peptide	Homo sapiens	109-117
32514572-2	2020	However, phosphate binder, ferric citrate (FC) overcomes the CKD-induced impairment of iron absorption and increases serum iron, transferrin saturation, and iron stores and reduces erythropoietin requirements in CKD/ESRD patients.	ferric citrate	27-41	erythropoietin	Homo sapiens	181-195
32514572-2	2020	However, phosphate binder, ferric citrate (FC) overcomes the CKD-induced impairment of iron absorption and increases serum iron, transferrin saturation, and iron stores and reduces erythropoietin requirements in CKD/ESRD patients.	ferric citrate	43-45	transferrin	Homo sapiens	129-140
32514572-2	2020	However, phosphate binder, ferric citrate (FC) overcomes the CKD-induced impairment of iron absorption and increases serum iron, transferrin saturation, and iron stores and reduces erythropoietin requirements in CKD/ESRD patients.	ferric citrate	43-45	erythropoietin	Homo sapiens	181-195
31668632-0	2019	Ferric citrate reduces fibroblast growth factor 23 levels and improves renal and cardiac function in a mouse model of chronic kidney disease.	ferric citrate	0-14	fibroblast growth factor 23	Mus musculus	23-50
31996496-8	2020	In Normal rat study, 3% ferric citrate treatment increased serum iron level and transferrin saturation (TSAT), and decreased serum phosphorus level, intact FGF23 (iFGF23) level, and urinary phosphorus excretion, but 0.3% ferric citrate treatment showed no effects.	ferric citrate	24-38	transferrin	Rattus norvegicus	80-91
31996496-8	2020	In Normal rat study, 3% ferric citrate treatment increased serum iron level and transferrin saturation (TSAT), and decreased serum phosphorus level, intact FGF23 (iFGF23) level, and urinary phosphorus excretion, but 0.3% ferric citrate treatment showed no effects.	ferric citrate	24-38	fibroblast growth factor 23	Rattus norvegicus	156-161
31668632-2	2019	Ferric citrate is an oral phosphate binder that decreases dietary phosphate absorption and serum FGF23 concentrations while increasing iron stores and hemoglobin in patients with CKD.	ferric citrate	0-14	fibroblast growth factor 23	Homo sapiens	97-102
31668632-7	2019	Circulating levels and bone expression of FGF23 were reduced in knockout mice given ferric citrate with more pronounced reductions observed when ferric citrate was initiated in early CKD.	ferric citrate	84-98	fibroblast growth factor 23	Mus musculus	42-47
31668632-7	2019	Circulating levels and bone expression of FGF23 were reduced in knockout mice given ferric citrate with more pronounced reductions observed when ferric citrate was initiated in early CKD.	ferric citrate	145-159	fibroblast growth factor 23	Mus musculus	42-47
31668632-10	2019	Thus, initiation of ferric citrate treatment early in the course of murine CKD lowered FGF23, slowed CKD progression, improved cardiac function and significantly improved survival.	ferric citrate	20-34	fibroblast growth factor 23	Mus musculus	87-92
31472185-2	2019	Human SH-SY5Y cells were pretreated with ferric citrate (FAC), and then were protected by PRO.	ferric citrate	41-55	FA complementation group C	Homo sapiens	57-60
31552988-8	2019	A broad range of modulated gene expression was associated with short- and long-term iron citrate exposition; however, after weaning of resistant cells, re-exposition to Fe induced a similar level of toxicity as observed in parental cells suggesting that a transient adaptation of gene expression was mounted.	ferric citrate	84-96	general transcription factor IIE subunit 1	Homo sapiens	169-171